MRNA · 10-Q · 2026Q3 · Full report

Supply Chain And Inventory

Moderna, Inc. · 2026-11-06 · Importance 26 · Surprise 24

Moderna reported inventory write-downs primarily for inventory exceeding expected demand, shelf-life expiration, and other inventory adjustments. Raw materials and work-in-progress have variable shelf lives, and the company expects to consume the majority of this inventory over the next three years. Finished-vaccine shelf lives are nine to twelve months for Spikevax, twelve months for mNEXSPIKE and mFLUSIVA, and eighteen months for mRESVIA.

Key facts

• Moderna had inventory on hand as of September 30, 2026, inclusive of inventory for its COVID, influenza and RSV vaccines; most raw materials and work-in-progress inventory was expected to be consumed over the next three years. source
• Spikevax had a shelf life of nine to twelve months; mNEXSPIKE and mFLUSIVA had shelf lives of twelve months; and mRESVIA had a shelf life of eighteen months. source